Abbreviations used:CI ( confidence interval), CT ( computed tomography), FDG ( fludeoxyglucose F 18), PASI ( Psoriasis Area and Severity Index), PET ( positron emission tomography), SD ( standard deviation), VIP ( Vascular Inflammation in Psoriasis)
- Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.Arch Dermatol. 2005; 141: 1537-1541
- Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.JAMA Dermatol. 2013; 149: 1173-1179
- Psoriasis and comorbid diseases: epidemiology.J Am Acad Dermatol. 2017; 76: 377-390
- Risk of myocardial infarction in patients with psoriasis.JAMA. 2006; 296: 1735-1741
- Psoriasis and the risk of diabetes: a prospective population-based cohort study.J Am Acad Dermatol. 2018; 78: 315-322 e311
- Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events.JACC Cardiovasc Imaging. 2013; 6: 1250-1259
- 18F-FDG PET/CT imaging in oncology.Ann Saudi Med. 2011; 31: 3-13
- Ethics. Incidental findings in brain imaging research.Science. 2006; 311: 783-784
- Prevalence and outcomes of incidental imaging findings: umbrella review.BMJ. 2018; 361: k2387
- Managing incidental findings in human subjects research: analysis and recommendations.J Law Med Ethics. 2008; 36 (211): 219-248
- Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial.Circ Cardiovasc Imaging. 2018; 11: e007394
- Vascular inflammation in psoriasis trial (The VIP Trial) (VIP).https://clinicaltrials.gov/ct2/show/NCT01553058Date: 2018Date accessed: July 1, 2018
- Study to evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in subjects with moderate to severe plaque psoriasis (VIP-S).https://clinicaltrials.gov/ct2/show/NCT02690701Date: 2018Date accessed: July 1, 2018
- Vascular inflammation in psoriasis-ustekinumab (VIP-U).https://clinicaltrials.gov/ct2/show/NCT02187172Date: 2018Date accessed: July 1, 2018
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.Lancet. 2007; 370: 1453-1457
- Incidental findings in imaging diagnostic tests: a systematic review.Br J Radiol. 2010; 83: 276-289
- Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening.CA Cancer J Clin. 2018; 68: 297-316
Medical Research Council (Great Britain), Opinion Leader Research Ltd, Wellcome Trust (London, England). Assessing Public Attitudes to Health Related Findings in Research: April 2012. Available at: https://wellcome.ac.uk/sites/default/files/wtvm055196_0.pdf. Accessed August 31, 2018.
- The ethics of how to manage incidental findings.CMAJ. 2014; 186: 655-656
- Incidental radiographic findings after injury: dedicated attention results in improved capture, documentation, and management.Surgery. 2010; 148: 618-624
- Incidental findings on total-body CT scans in trauma patients.Injury. 2014; 45: 840-844
- Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank - rationale, challenges and approaches.J Cardiovasc Magn Reson. 2013; 15: 46
- The need for closed-loop systems for management of abnormal test results.Ann Intern Med. 2018; 168: 820-821
- Biologic treatment for psoriasis and cancer: an increased risk for most cancers could not be ruled out.Br J Dermatol. 2018; 178: 19
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.Br J Dermatol. 2015; 172: 1395-1406
- Enrolling the uninsured in clinical trials: an ethical perspective.Crit Care Med. 2003; 31: S121-125
Funding sources: Supported in part by the National Institutes of Health (grant 5P30AR069589-03 ), the National Institutes of Health / National Heart, Lung, and Blood Institute (grant R01- HL111293 [to Dr Gelfand]), a grant from AbbVie for the Vascular Inflammation in Psoriasis trial [to Dr Gelfand]), a grant from Novartis Pharmaceuticals for the Vascular Inflammation in Psoriasis–Secukinumab trial (to Dr Gelfand), a grant from Janssen Scientific Affairs for the Vascular Inflammation in Psoriasis–Ustekinumab trial (to Dr Gelfand), and a medical dermatology fellowship from the National Psoriasis Foundation (to Dr Wan and Dr Noe).
Disclosure: Dr. Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Union Chimique Belge Data and Safety Monitoring Board, Sanofi, and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie , Janssen , Novartis Corp, Celgene , Ortho Dermatologics , and Pfizer Inc and has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company , Ortho Dermatologic , and Novartis . Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and he is also a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Mehta is a full-time US government employee and receives research grants to the National Heart, Lung, and Blood Institute from AbbVie , Janssen , Celgene , and Novartis . Dr Takeshita receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) and has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company . Dr Torigian is a cofounder of Quantitative Radiology Solutions LLC. Dr Alavi, Ms Alvarez, Dr Chiesa Fuxench, Dr Noe, Ms Papadopoulos, Dr Shin, Mr Werner, and Dr Wan have no conflicts of interest to disclosure.
Reprints not available from the authors.